JPH07508717A - テストステロンの濃度を上昇させる薬剤 - Google Patents
テストステロンの濃度を上昇させる薬剤Info
- Publication number
- JPH07508717A JPH07508717A JP5518840A JP51884093A JPH07508717A JP H07508717 A JPH07508717 A JP H07508717A JP 5518840 A JP5518840 A JP 5518840A JP 51884093 A JP51884093 A JP 51884093A JP H07508717 A JPH07508717 A JP H07508717A
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- drug
- administration
- drug according
- testosterone levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims description 56
- 229960003604 testosterone Drugs 0.000 title claims description 28
- 239000003814 drug Substances 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000000186 progesterone Substances 0.000 claims description 5
- 229960003387 progesterone Drugs 0.000 claims description 5
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical group O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 4
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 4
- 229960005471 androstenedione Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims 1
- 239000000321 herbal drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 12
- 230000035882 stress Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000003304 psychophysiological effect Effects 0.000 description 5
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 4
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- UOORRWUZONOOLO-OWOJBTEDSA-N (E)-1,3-dichloropropene Chemical compound ClC\C=C\Cl UOORRWUZONOOLO-OWOJBTEDSA-N 0.000 description 1
- -1 Alternatively Chemical compound 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012496 stress study Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (6)
- 1.ヒトの体内においてテストステロン濃度を上昇させる薬剤であって、少なく とも1つのテストステロンの前駆体を含有することを特徴とする薬剤。
- 2.前記前駆体がアンドロステンジオン、プロゲステロンまたは17−α−ヒド ロキシプロゲステロンであることを特徴とする請求の範囲第1項記載の薬剤。
- 3.投与スプレーを用いて経鼻投与により供給することができる生薬製剤である ことを特徴とする請求の範囲第1項または第2項記載の薬剤。
- 4.ポンプー押し当り3.5〜15mgの活性物質を含有することを特徴とする 請求の範囲第3項記載の薬剤。
- 5.経口投与用の徐放性の糖衣錠、デポー製剤あるいはバッカル錠剤の形状にあ る生薬製剤であることを特徴とする請求の範囲第1項または第2項記載の薬剤。
- 6.摂取単位当り50〜100mgの活性物質を含有することを特徴とする請求 の範囲第5項記載の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4214953A DE4214953C2 (de) | 1992-05-06 | 1992-05-06 | Arzneimittel zur Erhöhung des Testosteronspiegels |
DE4214953.3 | 1992-05-06 | ||
PCT/DE1993/000397 WO1993021924A1 (de) | 1992-05-06 | 1993-04-30 | Arzneimittel zur erhöhung des testosteronspiegels |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07508717A true JPH07508717A (ja) | 1995-09-28 |
JP3385583B2 JP3385583B2 (ja) | 2003-03-10 |
Family
ID=6458292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51884093A Expired - Lifetime JP3385583B2 (ja) | 1992-05-06 | 1993-04-30 | テストステロンの濃度を上昇させる薬剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5578588A (ja) |
EP (1) | EP0639077B1 (ja) |
JP (1) | JP3385583B2 (ja) |
CA (1) | CA2118030C (ja) |
DE (2) | DE4214953C2 (ja) |
ES (1) | ES2101317T3 (ja) |
WO (1) | WO1993021924A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4218291A1 (de) * | 1992-06-03 | 1993-12-09 | Mattern Et Partner Pharmazeuti | Dosierspray für pernasale Applikation |
AU8779898A (en) * | 1997-08-11 | 1999-03-01 | Weider Nutrition International, Inc. | Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
US5880117A (en) * | 1998-07-13 | 1999-03-09 | Arnold; Patrick | Use of 4-androstenediol to increase testosterone levels in humans |
US6391868B2 (en) * | 2000-05-10 | 2002-05-21 | Lpt Research, Inc. | Use of 5-alpha-androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17-beta-hydroxy-5-alpha-androst-1-en-3-one in humans |
US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
US20020183532A1 (en) * | 2001-06-01 | 2002-12-05 | Roberts William J. | Bioavailable prodrugs of androgenic steroids and related method |
US6740646B2 (en) | 2002-01-16 | 2004-05-25 | Biotest Laboratories, Llc | Bioavailable prodrugs of androgenic steroids and related method |
US20030134828A1 (en) * | 2002-01-16 | 2003-07-17 | Roberts William J. | Composition and method for increasing in vivo androgen concentration |
US6818668B2 (en) | 2002-04-12 | 2004-11-16 | Biotest Laboratories, Llc | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method |
DE10251028A1 (de) * | 2002-11-01 | 2004-05-19 | Jenapharm Gmbh & Co. Kg | Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
ES2825799T3 (es) | 2011-05-13 | 2021-05-17 | Acerus Biopharma Inc | Formulaciones en gel de testosterona intranasal de concentración de dosis más baja y uso de las mismas para tratar anorgasmia o trastorno del deseo sexual hipoactivo |
MX2013013369A (es) | 2011-05-15 | 2014-10-17 | Trimel Biopharma Srl | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3284303A (en) * | 1963-11-14 | 1966-11-08 | Warner Lambert Pharmaceutical | Orally active progesterone compositions |
BE898057A (fr) * | 1982-10-21 | 1984-02-15 | Mortimer Christopher H | Traitement de la calvitie androide. |
EP0163638A1 (en) * | 1983-11-30 | 1985-12-11 | BILTON, Gerald L. | Composition for supplemental treatment of male climacteric |
US5053403A (en) * | 1984-05-11 | 1991-10-01 | Norman Orentreich | Methods for treatment of male-pattern baldness |
NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
-
1992
- 1992-05-06 DE DE4214953A patent/DE4214953C2/de not_active Expired - Lifetime
-
1993
- 1993-04-30 US US08/335,729 patent/US5578588A/en not_active Expired - Lifetime
- 1993-04-30 DE DE59305968T patent/DE59305968D1/de not_active Expired - Lifetime
- 1993-04-30 ES ES93911730T patent/ES2101317T3/es not_active Expired - Lifetime
- 1993-04-30 WO PCT/DE1993/000397 patent/WO1993021924A1/de active IP Right Grant
- 1993-04-30 EP EP93911730A patent/EP0639077B1/de not_active Expired - Lifetime
- 1993-04-30 CA CA002118030A patent/CA2118030C/en not_active Expired - Lifetime
- 1993-04-30 JP JP51884093A patent/JP3385583B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2118030A1 (en) | 1993-11-11 |
JP3385583B2 (ja) | 2003-03-10 |
US5578588A (en) | 1996-11-26 |
DE4214953C2 (de) | 1995-05-18 |
EP0639077A1 (de) | 1995-02-22 |
EP0639077B1 (de) | 1997-03-26 |
DE4214953A1 (de) | 1993-11-11 |
WO1993021924A1 (de) | 1993-11-11 |
CA2118030C (en) | 1999-08-31 |
DE59305968D1 (de) | 1997-04-30 |
ES2101317T3 (es) | 1997-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Steiger | Sleep and endocrinology | |
OPPENHEIMER et al. | Disturbance of the pituitary-adrenal interrelationship in diseases of the central nervous system | |
Smith et al. | Opioid-induced androgen deficiency (OPIAD) | |
Klaiber et al. | Estrogen therapy for severe persistent depressions in women | |
Bimonte-Nelson et al. | Testosterone, but not nonaromatizable dihydrotestosterone, improves working memory and alters nerve growth factor levels in aged male rats | |
Ladisich | Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes | |
JPH07508717A (ja) | テストステロンの濃度を上昇させる薬剤 | |
WO1994001101A1 (en) | A method of treating reduced insulin-like growth factor and bone loss associated with aging | |
US5891853A (en) | Compositions and methods for enhancement of dehydroepiandrosterone | |
Lisoni et al. | Effect of an acute injection of melatonin on the basal secretion of hypophyseal hormones in prepubertal and pubertal healthy subjects | |
US6482858B1 (en) | (−)-hydroxycitric acid for wound healing and immunomodulation | |
Davidson et al. | Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers | |
Rizzo et al. | Amantadine in depression: relationship between behavioural effects and plasma levels | |
JPH0344324A (ja) | 性機能賦活剤 | |
Tennant et al. | Abnormal adrenal gland metabolism in opioid addicts: implications for clinical treatment | |
US6645954B2 (en) | Compositions comprising ethisterone or its derivatives | |
Zahorska-Markiewicz et al. | Neuropeptide Y in obese women during treatment with adrenergic modulation drugs | |
RU2480209C1 (ru) | Способ лечения нарушений менструального цикла у девушек-подростков с ожирением | |
EP0888116B1 (en) | Use of dehydroepiandrosterone for the treatment of addictions | |
EP3530267B1 (en) | Composition comprising pinitol for use in the prevention or treatment of female menopausal symptoms | |
US20050176829A1 (en) | Methods for treating hypothyroidism | |
KR102209475B1 (ko) | 우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도 | |
CA2113425C (en) | Androgens for stimulating the central nervous system and for treating osteoporosis | |
US6555531B1 (en) | Weight promoting composition, method, and product | |
JP6967012B2 (ja) | ウェーブバースト型不整脈を処置および予防するためのステロイドホルモン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090110 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090110 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100110 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110110 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120110 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130110 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |